



Office of Strategic Business Management
Revenue Maximization and Grants Coordination Division
Ryan White Title I Program
111 NW 1st Street • 22nd Floor
Miami, Florida 33128-1994
T 305-375-4742 • F 305-375-4454

miamidade.gov

September 12, 2005

Dear Ryan White Title I Service Provider:

Enclosed for your information and distribution is a **revised** Ryan White Title I Prescription Drugs Formulary sorted in the order of drug classification, brand name, and generic name. This new version will also be disseminated in electronic PDF format to facilitate its use and dissemination to all interested parties.

Effective September 12, 2005, at the recommendation of the Miami-Dade HIV/AIDS Partnership, the following medication has been added to the Formulary:

Drug Classification – Ophthalmic/Otic Preparations

Generic

Neomycin/Polymyxin B Sulfate with Dexamethasone*

Trade/Brand Name

Maxitrol

* It is important to note that Title I will **not** reimburse for this medication prior to the effective date of September 12, 2005.

In addition to the change indicated above, effective September 12, 2005, the following drug product is no longer restricted for the indication of corneal ulceration. Therefore, this restriction has been removed from the Title I Prescription Drugs Formulary:

Drug Classification – Ophthalmic/Otic Preparations

Generic

Ofloxacin**

Trade/Brand Name

Ocuflox


** It is important to note that this medication is not a new addition to the Title I Prescription Drugs Formulary, but rather the criteria restricted for the indication of corneal ulceration has been removed. It is also important to note that this medication is still restricted to Ophthalmologists **only** and remains otherwise unchanged for Ryan White Title I coverage of this drug product.

September 12, 2005

Page 2

IMPORTANT: The Ryan White Title I Prescription Drugs Formulary is revised periodically by the Miami-Dade HIV/AIDS Partnership. It is imperative that all revisions to the Formulary be carefully reviewed and understood by direct service staff and recipients of the Title I funded medications. Please notify program staff and clients immediately of these revisions. If further clarification is needed on these recent changes to the Formulary, please contact Theresa Wright-Williams, of my staff, at (305) 375-4742.

Sincerely,



Theresa Fiaño

Project Director

Office of Strategic Business Management

Enclosure

cc: Theresa Wright-Williams, Contracts Officer, OSBM
Daniel T. Wall, Assistant Director, OSBM
Carla Valle-Schwenk, Program Administrator, OSBM